[go: up one dir, main page]

BRPI0821894A2 - Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof - Google Patents

Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof

Info

Publication number
BRPI0821894A2
BRPI0821894A2 BRPI0821894-3A BRPI0821894A BRPI0821894A2 BR PI0821894 A2 BRPI0821894 A2 BR PI0821894A2 BR PI0821894 A BRPI0821894 A BR PI0821894A BR PI0821894 A2 BRPI0821894 A2 BR PI0821894A2
Authority
BR
Brazil
Prior art keywords
enzyme
subunit
phosphorylation state
enzyme complex
complex
Prior art date
Application number
BRPI0821894-3A
Other languages
Portuguese (pt)
Inventor
Robert Shorr
Robert Rodriguez
Paul Bingham
Laka W Boteju
Zuzana Zachar
Original Assignee
Robert Shorr
Robert Rodriguez
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robert Shorr, Robert Rodriguez filed Critical Robert Shorr
Publication of BRPI0821894A2 publication Critical patent/BRPI0821894A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0821894-3A 2008-04-04 2008-04-04 Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof BRPI0821894A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/004410 WO2009123597A1 (en) 2008-04-04 2008-04-04 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
BRPI0821894A2 true BRPI0821894A2 (en) 2015-07-21

Family

ID=41135840

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0821894-3A BRPI0821894A2 (en) 2008-04-04 2008-04-04 Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof

Country Status (10)

Country Link
EP (1) EP2268278A4 (en)
JP (1) JP2011516473A (en)
KR (1) KR20110025168A (en)
CN (1) CN102056605A (en)
AU (1) AU2008354009A1 (en)
BR (1) BRPI0821894A2 (en)
CA (1) CA2720396A1 (en)
IL (1) IL208387A0 (en)
MX (1) MX2010010867A (en)
WO (1) WO2009123597A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2590635B1 (en) 2010-07-08 2017-04-19 Wm. Wrigley Jr. Company Chewing gum containing a cross-linked gelatin matrix gum base
US9421234B2 (en) * 2011-05-20 2016-08-23 Nutramax Laboratories, Inc. Orally administrable compositions comprising avocado/soybean unsaponifiables and lipoic acid and methods of administration
US9708411B2 (en) * 2012-02-16 2017-07-18 The Penn Research Foundation Modulators of acyl-CoA lysocardiolipin acyltransferase 1 (ALCAT1) and uses thereof
JP6395724B2 (en) * 2012-12-19 2018-09-26 ロバート・ショア Pharmaceutical compounds
WO2015195070A1 (en) 2014-06-19 2015-12-23 Robert Shorr Pharmaceutical compounds
ES2747702T3 (en) 2014-06-19 2020-03-11 Rafael Pharmaceuticals Inc Pharmaceutical compounds
CN110590624B (en) * 2019-09-26 2021-02-26 苏州富士莱医药股份有限公司 Preparation method of lipoic acid derivative 8- (ethyl disulfide) -6- (phenyl disulfide) caprylic acid
EP4380567B1 (en) * 2021-08-04 2025-05-07 Cytacoat AB Disulfide compounds as medicaments
CN118236491A (en) * 2022-12-23 2024-06-25 中国科学院上海营养与健康研究所 PDK4 as a target for cell senescence intervention and its application in chemotherapy and anti-cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2853497A (en) * 1953-12-04 1958-09-23 Merck & Co Inc 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
US2789991A (en) * 1954-05-20 1957-04-23 American Cyanamid Co Substituted disulfones
JPS61198148A (en) * 1985-01-29 1986-09-02 Fuji Photo Film Co Ltd Silver halide photographic sensitive material
GB9618934D0 (en) * 1996-09-11 1996-10-23 Univ London Inositol phosphoglycans for therapeutic use in the treatment of diabetes and obesity
CA2323726C (en) * 1998-03-20 2005-02-08 Benitec Australia Ltd. Control of gene expression
FR2777001B1 (en) * 1998-04-01 2000-06-09 Cird Galderma 6,8-DIMERCAPTOOCTANOIC ACID DERIVATIVES SUBSTITUTED IN 6-S AND / OR 8-S BY RADICAL (3-METHYLTHIOPROPANOYL) AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CANCER TUMORS
EP1486495B1 (en) * 1998-10-26 2009-12-09 The Research Foundation of State University of New York Salts of lipoic acid derivatives and their use in treatment of disease
DE19904794A1 (en) * 1999-02-05 2000-08-10 Biotechnolog Forschung Gmbh Methods for improving the primary metabolism of mammalian cell lines
US6284786B1 (en) * 1999-02-16 2001-09-04 The Center For The Improvement Of Human Functioning, Int'l., Inc. Treatment of cancer using lipoic acid in combination with ascorbic acid
AR042572A1 (en) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic DERIVATIVES OF LIPOIC ACID, PROCEDURE FOR THE PREPARATION, MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF SUCH DERIVATIVES FOR THE PREPARATION OF THE REFERRED MEDICATIONS
IT1312060B1 (en) * 1999-04-09 2002-04-04 Antibioticos Spa USE OF ALPHA LIPOIC ACID IN ANTIMETASTATIC TREATMENT.
US7108977B2 (en) * 2000-05-19 2006-09-19 Hoffmann-La Roche Inc. Process for determining the tumoricidal potential of a sample the use of a nucleic acid which is downregulated in human tumor cells
WO2006119355A2 (en) * 2005-05-03 2006-11-09 Albert Einstein College Of Medicine Of Yeshiva University Mammalian hypothalamic nutrient modulation of glucose metabolism
WO2007072219A2 (en) * 2005-09-21 2007-06-28 Aurelium Biopharma Inc. Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
JP5480804B2 (en) * 2007-04-18 2014-04-23 コーナーストーン ファーマシューティカルズ，インコーポレーテッド Pharmaceutical preparation containing lipoic acid derivative
CN101765370B (en) * 2007-04-18 2014-06-25 基石制药公司 Lipoic acid derivatives
WO2009110859A1 (en) * 2008-03-04 2009-09-11 Robert Shorr Modulation of enzymatic structure, activity, and/or expression level

Also Published As

Publication number Publication date
MX2010010867A (en) 2011-05-25
EP2268278A1 (en) 2011-01-05
CA2720396A1 (en) 2009-10-08
EP2268278A4 (en) 2011-11-09
JP2011516473A (en) 2011-05-26
KR20110025168A (en) 2011-03-09
IL208387A0 (en) 2010-12-30
CN102056605A (en) 2011-05-11
WO2009123597A1 (en) 2009-10-08
AU2008354009A1 (en) 2009-10-08

Similar Documents

Publication Publication Date Title
BRPI0821894A2 (en) Pharmaceutically acceptable phosphorylation state modulator of at least one enzyme and / or enzyme complex, or subunits thereof, in mitochondria of diseased cells of warm-blooded animals, including humans, method of modulating at least one enzyme or enzyme complex , or a subunit thereof, in a patient having a disease, condition, or syndrome including a change in the phosphorylation state of at least one enzyme and / or an enzyme complex, or a subunit thereof, and method to diagnose and predict benefit in a patient who has symptoms of a disease, condition, or syndrome that includes a change in the phosphorylation state of at least one enzyme and / or enzyme complex, or a subunit thereof
BRPI1015236A2 (en) methods for modulating an inflammatory response to ameliorate an inflammatory disease, disorder or condition in an animal, to treat an animal at risk for an inflammatory disease, disorder or condition, to inhibit factor xi expression in an animal, to reduce the risk of an inflammatory disease, disorder or condition, in an animal, to treat an animal at risk for an inflammatory disease, and to treat an animal having an inflammatory disease, and use of a factor xi-labeled compound
BRPI0821895A2 (en) PHARMACEUTICAL COMPOSITION, METHOD OF TREATMENT OR PREVENTION OF A DISEASE, A CONDITION AND SYMPTOMS OF THE SAME IN HOT BLOOD ANIMALS, INCLUDING HUMAN BEINGS, METHOD FOR PREPARATION OF THE PHARMACEUTICAL COMPOSITION, METHOD DIAGNOSIS
BR112012031389A2 (en) Method to Predict Clinical Outcomes for Melanoma Patients Using Circulating Blood Melanoma Cells
BRPI0815175A2 (en) A device and procedure for the diagnosis or preparation of the diagnosis and / or monitoring of therapy for inflammatory diseases such as rheumatoid arthritis.
BRPI0919017A2 (en) methods for increasing fetal hemoglobin levels in a cell and in mammal in need thereof, and for identifying a bcl11a expression or activity modulator
BRPI0813926A2 (en) USE OF A SUBSTANCE, COMPOSITION AND METHODS FOR ASSESSING ACTIVE PRINCIPLES INHIBITING TRAINING OF AGES AND COSMETIC CARE.
BR112015000685A2 (en) method for identifying clinical risk in a patient possessing or suspected of having an influenza infection, method for identifying influenza or viral pneumonia in a patient, kit, method for assessing the effectiveness of an agent for treating influenza and for reduce the severity of the disease in an individual exposed to an influenza virus.
MX392330B (en) PHARMACEUTICAL USE OF A STEP-ESCALATION ACID SPHINGOMYELINASE (ASM) FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY.
BRPI0813456A2 (en) COMPOSITION, USE OF THE SAME, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A MAMMAL WITH A DISORDER AND DISEASE
BRPI1007626A2 (en) imaging method by a moving portion of a patient's body placed on an examination volume of an rm device, rm device, rm device, to perform the method and computer program on an rm device
BRPI0819992A8 (en) METHODS FOR OPERATING A MEDICAL DEVICE AND ENABLING NUMEROUS OPERATIONAL ASPECTS OF A MEDICAL DEVICE, AND, MEDICAL DEVICE
BRPI0918398A2 (en) Method for diagnosing a physiological abnormality in a patient, System for diagnosing a physiological abnormality in a patient, Catheter and Device for diagnosing a physiological abnormality in a patient
CY1121852T1 (en) FORMULATIONS AND METHODS OF PREPARING FORMULATIONS FOR USE IN COLON CLEANSING
BRPI0921011A2 (en) methods for causing at least one of an increase in oral moistening and relief of a symptom associated with hyposalivation, and an increase in oral moistening levels, and oral care product.
BRPI0819195A2 (en) methods for treating scleroderma in a patient in need of such treatment and for alleviating one or more of the symptoms associated with scleroderma in a patient in need of such treatment.
BRPI0821176A2 (en) phosphorylation state modulator of at least one enzyme complex, method for modulating the pdh complex in a patient presenting a disease, condition, or syndrome, and method for diagnosing and predicting benefit in a patient presenting symptoms of a disease, condition , or syndrome caused by a change in the structure and / or activity of the pdh complex
BR112012030051A2 (en) oral health index
BR112016012233A8 (en) compositions comprising cinnamaldehyde, and its uses
Meyer et al. The bat and ball problem
Girawan et al. Comparison of endoscopic gastric mucosa features after administration of piroxicam to meloxicam and their correlation with dyspepsia symptoms in elderly patient with knee osteoarthritis.
BRPI0920607A2 (en) immunogenic composition, pharmaceutical composition, use of one or more s proteins. uberis anchored to sortase in the preparation of a medicament, and methods for protecting a human animal or not from the effects of infection with s. uberis, and to enhance an immune response in a human or non-human animal.
Adama et al. Biochemical Responses of Yankasa Sheep to Experimental Fasciola gigantic Infection in Zaria, Nigeria
BRPI0822420A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS TO TREAT A DISEASE IN AN ANIMAL AND TO TREAT A PATIENT WHO GOES THROUGH A TAREPIA.
Karateev Aceclofenac in rheumatology: The golden mean

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]